What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

CRISPR Knock-In: Mechanisms, Methods, and Practical Pitfalls

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to CRISPR Knock-In

CRISPR knock-in refers to the precise insertion of an exogenous DNA sequence—such as a fluorescent tag, a point mutation, a loxP site, or a full coding sequence—at a defined genomic locus using the CRISPR-Cas9 system. Unlike CRISPR knockout, which disrupts gene function by introducing insertions or deletions (indels) that shift the reading frame or create premature stop codons, knock-in editing aims to install a specific sequence change without necessarily destroying the target gene's function. The distinction matters: a knockout is a loss-of-function allele generated by error-prone repair, whereas a knock-in is a gain-of-function, replacement, or tagging event that requires a supplied repair template.

The core challenge of knock-in editing is that the cell's default response to a Cas9-induced double-strand break (DSB) is non-homologous end joining (NHEJ), which is error-prone and produces indels. Homology-directed repair (HDR), the pathway that can copy information from an exogenous template, is naturally suppressed in most cell types and is largely restricted to the S/G2 phases of the cell cycle. The practical goal of any knock-in experiment is therefore to bias the repair outcome toward HDR, deliver the repair template efficiently, and then identify the rare correctly edited cells among a population dominated by NHEJ events and unedited cells.

What is CRISPR Knock-In?

A CRISPR knock-in experiment requires three components: a Cas9 nuclease (or a variant such as a nickase), a guide RNA (gRNA) that directs Cas9 to a specific genomic sequence adjacent to a protospacer adjacent motif (PAM), and a donor template containing the desired sequence flanked by homology arms. When Cas9 generates a DSB at the target site, the cell can use the donor template to repair the break via HDR, copying the desired sequence into the genome. The efficiency of this process is typically low—often 1–10% in immortalized cell lines and considerably lower in primary cells or embryos—which is why selection and screening strategies are essential.

Knock-in editing can be used to introduce point mutations that mimic human disease alleles, insert epitope tags (e.g., FLAG, HA, Myc) at endogenous loci to study protein localization or interactions, create conditional alleles by inserting loxP sites flanking critical exons, or fuse fluorescent proteins (e.g., GFP, mCherry) to endogenous genes for live-cell imaging. The scale of the insertion ranges from a single nucleotide substitution to multi-kilobase cassettes, and the choice of donor template and delivery method scales accordingly.

Applications of Knock-In Editing

Knock-in editing has become a cornerstone of functional genomics and disease modeling. In cell lines, it enables endogenous-level expression of tagged proteins, avoiding the artifacts associated with overexpression from heterologous promoters. In animal models, knock-in mice carrying patient-specific mutations provide faithful recapitulation of human genetic diseases. In the context of CRISPR in Medicine, knock-in strategies are being explored for therapeutic gene correction, such as repairing the CFTR ΔF508 mutation in cystic fibrosis patient-derived cells or inserting a functional copy of a mutated gene at its endogenous locus.

The same principles apply whether the goal is a single-nucleotide correction or a large gene insertion, but the methods diverge significantly. Small edits (under ~200 bp) are best accomplished with single-stranded oligodeoxynucleotides (ssODNs), while larger insertions require plasmid or viral donors. Understanding the repair mechanisms that govern these outcomes is the first step toward designing a successful experiment.

Mechanisms of CRISPR-Mediated Knock-In

The outcome of a CRISPR-induced DSB is determined by the competing DNA repair pathways available to the cell. The choice between them is influenced by cell cycle phase, the structure of the DNA ends, the availability of a homologous template, and the activity of key repair factors. A mechanistic understanding of these pathways is essential for designing donors and choosing strategies to bias repair toward the desired knock-in event.

Homology-Directed Repair (HDR)

HDR is the pathway that enables precise knock-in by copying sequence information from a homologous donor template. In mammalian cells, HDR is initiated by resection of the 5' ends at the DSB, generating 3' single-stranded DNA overhangs. These overhangs are coated by RPA and then replaced by RAD51, which promotes strand invasion into a homologous duplex—either the sister chromatid or an exogenous donor template. The invading 3' end primes DNA synthesis, copying information from the template, and the process is resolved through Holliday junction formation and resolution or through synthesis-dependent strand annealing (SDSA).

HDR is tightly cell-cycle regulated. The key commitment step—5' end resection—is promoted by cyclin-dependent kinase (CDK) activity, which is high in S and G2 phases. In G1, resection is blocked by the 53BP1 pathway, which instead promotes NHEJ. This means that HDR-mediated knock-in is inherently limited to cells that are actively cycling and in the S/G2 window at the time of the DSB. For most immortalized cell lines, this fraction is roughly 20–40% at any given moment, which is a major reason why HDR efficiency is low even under optimal conditions.

The donor template for HDR must share homology with the sequences flanking the DSB. For plasmid donors, homology arms of 500–1000 bp on each side are typical. For ssODNs, arms of 30–60 bp are sufficient for small edits. The DSB should be positioned as close as possible to the desired edit—ideally within 10 bp—because HDR tract lengths are short and the efficiency of incorporating distant mutations drops sharply with distance.

Non-Homologous End Joining (NHEJ) and MMEJ

NHEJ is the dominant DSB repair pathway in mammalian cells and is active throughout the cell cycle. It involves direct ligation of the broken DNA ends, often with minimal or no processing. Because the ends are frequently resected by nucleases or modified by polymerases before ligation, NHEJ typically introduces small insertions or deletions (indels) at the break site. These indels are the basis of CRISPR knockout, but they are a competing, undesirable outcome in knock-in experiments.

Classical NHEJ (cNHEJ) requires Ku70/Ku80 heterodimers, DNA-PKcs, and ligase IV. It is fast and efficient but does not use a homologous template. A related pathway, microhomology-mediated end joining (MMEJ), also called alternative NHEJ, uses short stretches of homology (5–25 bp) that are exposed by limited resection to align the ends before ligation. MMEJ is often associated with larger deletions and is dependent on PARP1, CtIP, and ligase III.

For knock-in purposes, NHEJ is usually a nuisance—it competes with HDR and produces indels that must be screened out. However, NHEJ can be exploited for certain types of knock-in, such as the targeted insertion of a donor cassette into a DSB without homology arms, a strategy sometimes called "homology-independent targeted integration" (HITI). This approach relies on the cell ligating the donor into the break via NHEJ, but it suffers from the same imprecision as NHEJ and can result in insertions in either orientation or with junctional indels.

Microhomology-Mediated End Joining

MMEJ deserves separate mention because it has been harnessed for a specific knock-in strategy known as microhomology-mediated end joining-based knock-in. In this approach, the donor template is designed with short microhomology arms (10–40 bp) that are complementary to sequences immediately flanking the DSB. After Cas9 cleavage, the cell resects the ends, exposing the microhomologies, and the donor is annealed and ligated into the break.

MMEJ-based knock-in has several advantages over HDR: it is active in G1 phase, it does not require long homology arms, and it can achieve higher efficiencies in some cell types, particularly in post-mitotic cells and in vivo. The trade-off is that the junctions are less precise—small deletions or insertions at the boundaries are common—and the orientation of the insert is determined by the design of the microhomology arms. This strategy is particularly useful for inserting large cassettes (e.g., fluorescent reporters) where precise junction sequence is less critical than the presence of the full-length insert.

Designing Donor Templates for Knock-In

The donor template is the single most important determinant of knock-in success. Its design must account for the size of the insertion, the repair pathway you intend to exploit, and the downstream screening strategy. Three main formats are used: plasmid donors, single-stranded oligodeoxynucleotides (ssODNs), and viral vectors.

Plasmid Donors

Plasmid donors are circular double-stranded DNA molecules that carry the desired insertion flanked by homology arms. They are the standard choice for insertions larger than ~200 bp, such as fluorescent protein tags, drug resistance cassettes, or full coding sequences. Homology arms of 500–1000 bp are recommended for each side; longer arms (up to 2–3 kb) can improve efficiency but also increase the difficulty of plasmid construction.

A critical design consideration is whether to linearize the plasmid donor at a site within the homology region. Linearization creates a double-stranded break in the donor that mimics the genomic DSB and can improve HDR efficiency by providing a more accessible substrate for strand invasion. This is typically done by including a unique restriction site between the homology arms or by using a Cas9 cleavage site that is distinct from the genomic target.

Plasmid donors should also include silent mutations in the gRNA target sequence or PAM sequence to prevent re-cleavage of the edited locus. If the donor carries the same protospacer as the genomic target, Cas9 will recognize and cleave the donor before it can be used as a repair template, and it will also re-cleave the successfully edited genome. Introducing synonymous codon changes in the protospacer region of the donor avoids this problem without altering the protein sequence.

Single-Stranded Oligodeoxynucleotides (ssODNs)

For small edits—point mutations, short epitope tags, or loxP sites under 200 bp—ssODNs are the preferred donor format. They are chemically synthesized, inexpensive, and can be delivered at high concentrations. A typical ssODN is 100–200 nucleotides long, with the desired edit positioned centrally and 30–60 nucleotides of homology on each side.

The design rules for ssODNs are well established. The edit should be placed as close to the Cas9 cut site as possible; efficiency drops by roughly 50% for every 10 bp of distance. If the edit is a point mutation, it should be flanked by silent mutations in the gRNA seed region and PAM to prevent re-cleavage. For example, if you are introducing a disease-associated missense mutation, you should also alter the PAM sequence (e.g., from NGG to NGA) or introduce synonymous changes in the seed region (positions 1–12 of the protospacer) to block Cas9 binding.

ssODNs can be delivered as either sense or antisense strands; both work, but the strand that is complementary to the non-target strand (i.e., the strand that is not bound by the gRNA) is often slightly more efficient. For edits that involve inserting a sequence, the ssODN should be designed so that the inserted sequence is flanked by homology arms that match the genomic sequence on both sides of the cut.

Homology Arm Design and Silent Mutations

Regardless of donor format, the homology arms must match the genomic sequence exactly. Any polymorphism or sequencing error in the arms will reduce HDR efficiency, sometimes dramatically. It is therefore essential to sequence the target locus in the specific cell line or animal strain you are using before designing the donor, rather than relying on reference genome sequences.

Silent mutations serve two purposes in donor design. First, they prevent re-cleavage of the edited locus by Cas9, as described above. Second, they can introduce a restriction enzyme site or a primer mismatch that facilitates screening. For example, adding a silent mutation that creates an RFLP (restriction fragment length polymorphism) allows you to distinguish edited clones by PCR followed by restriction digest. Similarly, a silent mutation at the 3' end of a genotyping primer can be used for allele-specific PCR.

For large insertions, the donor should also include a selection marker, such as a puromycin or neomycin resistance cassette, flanked by loxP sites or FRT sites so that it can be removed after selection. The marker is typically placed outside the homology arms or between them, depending on whether you want it retained in the final allele. If the goal is a clean insertion (e.g., a C-terminal GFP tag), the selection cassette should be placed downstream of the stop codon and removed by Cre or Flp recombination after clonal selection.

Delivery Methods for CRISPR Components and Donors

The delivery method determines the efficiency of co-delivery of Cas9, gRNA, and donor template, as well as the toxicity and the types of cells that can be edited. No single method is optimal for all applications; the choice depends on cell type, throughput, and whether the goal is transient editing or stable integration.

Electroporation and Nucleofection

Electroporation uses a brief electrical pulse to create transient pores in the cell membrane, allowing nucleic acids to enter. Nucleofection is a specialized form of electroporation developed by Lonza that uses cell-type-specific buffers and electrical programs to deliver nucleic acids directly to the nucleus. These methods are highly efficient for immortalized cell lines, primary cells, and stem cells, and they allow precise control over the amount of Cas9 and donor delivered.

For ribonucleoprotein (RNP) delivery—where purified Cas9 protein is complexed with in vitro-transcribed gRNA—electroporation is the method of choice. RNPs are active immediately, degrade within 24–48 hours, and have lower off-target activity than plasmid-based delivery because the exposure time is shorter. The donor can be co-electroporated as an ssODN or plasmid. Typical conditions for a 10 µL reaction in a 96-well format use 10–20 pmol of Cas9 protein, 20–40 pmol of gRNA, and 100–200 pmol of ssODN or 1–2 µg of plasmid donor.

Electroporation is also compatible with high-throughput workflows. For example, arrays of gRNAs and donors can be electroporated into cells in 96-well plates, enabling parallel knock-in of many loci. The main drawback is cell toxicity; some primary cells do not survive electroporation well, and optimization of pulse conditions is often required.

Lipofection

Lipofection uses cationic lipid reagents to form complexes with nucleic acids that are taken up by cells via endocytosis. It is gentler than electroporation and works well for plasmid-based delivery of Cas9 and gRNA, but it is generally less efficient for delivering ssODNs and RNPs. Lipofection is the standard method for HEK293T, HeLa, and other easily transfectable cell lines, but it is poorly suited for primary cells, suspension cells, and stem cells.

For knock-in experiments, lipofection is most useful when the donor is a large plasmid and the goal is to generate stable cell lines. The efficiency of co-delivery of Cas9 plasmid, gRNA plasmid, and donor plasmid is lower than electroporation, and the prolonged expression of Cas9 from a plasmid increases off-target effects. If you use lipofection, consider using a Cas9 expression plasmid with a fluorescent marker (e.g., GFP) so that you can enrich for transfected cells by flow cytometry before plating for single-cell clones.

AAV and Lentiviral Vectors

Viral vectors are the preferred delivery method for primary cells, in vivo editing, and large donor templates. Adeno-associated virus (AAV) is a single-stranded DNA virus that can package up to ~4.7 kb of donor template. AAV does not integrate into the genome efficiently on its own; instead, it persists as an episome, which makes it an excellent donor for HDR. The donor is delivered as an AAV vector with homology arms flanking the insertion, and the virus infects both dividing and non-dividing cells.

AAV serotype choice matters: AAV2, AAV6, and AAV-DJ are commonly used for cell lines and hematopoietic cells, while AAV8 and AAV9 are used for liver and muscle in vivo. The multiplicity of infection (MOI) should be titrated, as high MOIs can cause toxicity. One limitation of AAV is that the single-stranded genome can integrate randomly at low frequency, and the ITRs (inverted terminal repeats) can be recognized by the DNA repair machinery, leading to concatemer formation.

Lentiviral vectors are retroviruses that integrate into the genome, making them suitable for stable delivery of Cas9 and gRNA, but they are less useful for donor delivery because random integration of the donor is a major source of false positives. For knock-in, lentivirus is typically used to deliver Cas9 and gRNA stably, and the donor is delivered separately by electroporation or AAV. This two-step approach allows you to establish a cell line with inducible Cas9 expression, then introduce the donor at a defined time to control the cell cycle stage.

Enhancing Knock-In Efficiency

Baseline HDR efficiency is often frustratingly low, particularly in primary cells and in vivo. Several strategies can shift the balance from NHEJ toward HDR, and they can be combined for additive effects.

Cell Cycle Synchronization

Because HDR is restricted to S/G2, synchronizing cells to these phases at the time of Cas9 delivery can increase knock-in efficiency. The most common approach is to treat cells with a CDK inhibitor such as roscovitine or with nocodazole, which arrests cells in G2/M. Alternatively, aphidicolin or thymidine blocks arrest cells at the G1/S boundary; releasing the block and delivering Cas9 2–4 hours later catches cells in S phase.

A more elegant approach is to use a Cas9 fusion protein that is degraded in G1. For example, fusing Cas9 to a fragment of Geminin, which is ubiquitinated and degraded in G1 but stable in S/G2, restricts Cas9 activity to the phases where HDR is active. This "cell-cycle-timed" Cas9 has been shown to improve HDR efficiency by several-fold in some cell types.

Chemical Inhibitors of NHEJ

Small-molecule inhibitors of NHEJ can bias repair toward HDR. The most widely used is SCR7, which inhibits DNA ligase IV, the enzyme that catalyzes the final ligation step in cNHEJ. SCR7 is typically used at 1–10 µM, added immediately after electroporation and maintained for 24–48 hours. Its efficacy varies by cell type, and it can be toxic at high concentrations.

Other inhibitors target downstream effectors. NU7441 and KU-57788 inhibit DNA-PKcs, a kinase required for NHEJ. Mirin inhibits MRE11, a nuclease involved in both NHEJ and HDR, and its effects are context-dependent. The combination of SCR7 with cell cycle synchronization can produce additive improvements, but the magnitude of the effect is rarely more than 2–3-fold.

Cas9 Variants and Fusions

Several engineered Cas9 variants have been developed to enhance HDR. Cas9 nickases (D10A or H840A) create single-strand breaks instead of DSBs. When paired with two gRNAs that nick opposite strands, they generate a DSB with long 5' overhangs that are less efficiently repaired by NHEJ and more efficiently repaired by HDR. The "double-nick" strategy reduces off-target effects and can improve HDR:donor integration ratios, though the absolute efficiency is often lower than with wild-type Cas9.

Fusing Cas9 to HDR-promoting proteins is another active area. Cas9 fused to CtIP, a resection factor, has been reported to enhance HDR by promoting 5' end resection. Cas9 fused to RAD51 or to a peptide derived from the adenovirus E1B protein has also been explored. These fusions are delivered as plasmids or RNPs and can be combined with chemical inhibitors. The trade-off is increased complexity and the risk of altered Cas9 activity or specificity.

Selection and Screening of Knock-In Clones

Even with optimized delivery and enhancement strategies, the majority of cells will be unedited or will carry indels. Identifying correctly edited clones requires a robust selection and screening pipeline.

Reporter Systems

Fluorescent reporters are the most convenient way to enrich for edited cells. The donor can be designed to include a fluorescent protein (e.g., GFP) as part of the insertion, allowing you to sort GFP-positive cells by flow cytometry. For small edits that do not include a fluorescent marker, a surrogate reporter can be used: a plasmid carrying a GFP gene that is activated only when HDR occurs, co-delivered with the donor. GFP-positive cells are enriched for HDR activity, and the desired edit is found at a higher frequency among them.

Another strategy is to use a donor that carries a fluorescent protein flanked by self-cleaving peptide sequences (e.g., P2A or T2A) fused to the target gene. This allows the fluorescent protein to be expressed as a separate polypeptide from the same mRNA, enabling live-cell detection of the edited allele without interfering with the target protein's function.

Antibiotic Selection

For large insertions, including a drug resistance cassette (puromycin, neomycin, hygromycin) in the donor allows selection of cells that have integrated the donor. The cassette can be placed between the homology arms, replacing the target sequence, or outside the arms for a "knock-in with selection" strategy where the cassette is retained. After selection, clones must be screened to confirm that the cassette is at the correct locus and not randomly integrated.

The concentration of the antibiotic must be titrated for each cell line. For puromycin, a typical working concentration is 1–2 µg/mL for HEK293T cells, but it should be determined by a kill curve. Selection should be initiated 24–48 hours after transfection and maintained for 7–14 days until colonies appear.

PCR and Sequencing Validation

PCR-based genotyping is the gold standard for confirming knock-in events. The design of genotyping primers is critical: one primer should anneal outside the homology arm (in the genomic sequence) and the other inside the inserted sequence. This "outward-facing" primer pair will only amplify if the donor has integrated at the correct locus. A second primer pair spanning the entire insertion can confirm the junction on the other side.

For small edits, a common approach is to amplify the target region and perform Sanger sequencing. If the edit introduces a restriction site, a restriction digest of the PCR product can be used for rapid screening. For large insertions, long-range PCR with a high-fidelity polymerase (e.g., Q5 or Phusion) and an extension time of 1 minute per kb is recommended. Southern blotting is rarely necessary but can be used to confirm single-copy integration.

Common Pitfalls and Troubleshooting

Low HDR Efficiency

The most common failure mode is simply too few edited cells. If your knock-in efficiency is below 1%, consider the following: (1) confirm that your gRNA is active by measuring indel frequency at the target locus—if indels are below 30%, the gRNA is poor and should be redesigned; (2) verify that your donor is pure and at the correct concentration—degraded ssODNs or supercoiled plasmids that are not linearized can reduce HDR; (3) check the distance between the cut site and the edit—if it is more than 20 bp, redesign the donor to place the edit closer; (4) ensure that your cells are in S/G2 at the time of delivery—consider synchronization or a Geminin-Cas9 fusion; (5) test multiple delivery conditions, including RNP electroporation, which is often more efficient than plasmid transfection.

Off-Target Effects

Off-target cleavage can produce indels at unintended loci, confounding phenotypic analysis. The risk is higher with plasmid-based Cas9 delivery because expression persists for days. Using RNP delivery reduces off-target activity because the protein is degraded within 24–48 hours. You can also use a high-fidelity Cas9 variant such as SpCas9-HF1 or eSpCas9, which have reduced off-target activity while maintaining on-target efficiency. For a detailed discussion of this topic, see CRISPR Off Target Effects. After generating clones, it is prudent to check the top predicted off-target sites by PCR and sequencing.

Mosaicism in Embryos

When performing knock-in in embryos (e.g., for mouse or zebrafish models), the edited cells may not all carry the same allele. Mosaicism arises because Cas9 and the donor are active at different times during early cleavage divisions, and each cell can undergo independent repair events. To reduce mosaicism, deliver Cas9 as an RNP rather than as mRNA or plasmid, because RNP activity is more transient and uniform. Also, inject the donor at a high concentration and use a gRNA that is highly active so that editing occurs in the first cell cycle. Screening F0 animals by PCR and sequencing of multiple tissues is essential, and germline transmission should be confirmed by breeding.

Summary and Best Practices

Key Considerations

Before starting a knock-in experiment, define the minimal edit that achieves your goal. If you only need to tag a protein, a small epitope tag (e.g., FLAG) is easier to knock in than GFP. If you need a point mutation, use an ssODN; if you need a large cassette, use a plasmid or AAV donor. Always sequence the target locus in your specific cell line, design silent mutations to prevent re-cleavage, and choose a delivery method that matches your cell type.

Step-by-Step Workflow

Design and validate gRNA: Use a tool like CRISPRscan or sgRNA Scorer to select a gRNA with high on-target and low off-target scores. Test indel efficiency by T7E1 assay or Sanger sequencing 48 hours after transfection.
Design and order donor: For ssODNs, order 100–200 nt oligos with 30–60 nt homology arms. For plasmids, clone homology arms and the insertion into a vector with a selection marker.
Deliver Cas9, gRNA, and donor: Use RNP electroporation for most cell lines. Include a fluorescent marker or co-deliver a surrogate reporter to enable enrichment.
Enhance HDR if needed: Synchronize cells in S/G2, add SCR7, or use a Cas9-CtIP fusion.
Select and screen: Apply antibiotic selection if a resistance cassette is present. After 7–14 days, pick colonies and screen by PCR and sequencing.
Validate: Confirm the edit at the DNA level, check for off-target indels, and verify protein expression by Western blot or immunofluorescence.

Frequently Asked Questions

What is the difference between CRISPR knock-in and knockout?

A knockout disrupts a gene by introducing indels that cause frameshifts or premature stop codons, typically via NHEJ repair of a Cas9-induced DSB. A knock-in inserts a specific exogenous sequence at a defined locus using a donor template and HDR (or MMEJ). Knockout destroys gene function; knock-in modifies or adds function.

What is the principle of CRISPR knock-in?

Cas9 creates a DSB at a gRNA-specified locus. The cell repairs the break either by error-prone NHEJ or by HDR. If a donor template with homology to the break site is provided, HDR can copy the desired sequence into the genome, achieving precise insertion.

How do I design a donor template for CRISPR knock-in?

For small edits (<200 bp), use an ssODN with 30–60 nt homology arms and place the edit within 10 bp of the cut site. For larger insertions, use a plasmid with 500–1000 bp homology arms, linearized within the homology region. Always include silent mutations in the gRNA seed and PAM sequences to prevent re-cleavage.

What is the best delivery method for CRISPR knock-in?

Electroporation of Cas9 RNP complexes with ssODN or plasmid donors is the most efficient and least toxic method for most cell types. AAV is preferred for in vivo delivery or for large donors in primary cells. Lipofection is only suitable for easily transfectable cell lines.

Why is my CRISPR knock-in efficiency so low?

The most common causes are poor gRNA activity, a donor with insufficient homology or incorrect sequence, a large distance between the cut site and the edit, and delivery of Cas9 during G1 phase. Check indel efficiency, redesign the donor, and consider cell cycle synchronization or NHEJ inhibitors.

How can I select cells that have undergone knock-in?

Include a fluorescent marker in the donor for FACS enrichment, or a drug resistance cassette for antibiotic selection. For small edits without markers, use a surrogate reporter or screen colonies by PCR and sequencing.

What are common pitfalls in CRISPR knock-in experiments?

Low HDR efficiency, off-target indels, mosaicism in embryos, random integration of the donor, and re-cleavage of the edited locus are the most frequent problems. Each can be addressed by careful donor design, RNP delivery, and rigorous screening.

Key Takeaways

CRISPR knock-in requires a DSB, a donor template, and a bias toward HDR; NHEJ is the default and must be suppressed or avoided.
Donor design is the most critical variable: match homology arms to your exact cell line sequence, place edits close to the cut, and include silent mutations to prevent re-cleavage.
ssODNs are optimal for small edits; plasmid or AAV donors are required for large insertions.
RNP electroporation is the most reliable delivery method for efficiency and low off-target activity.
HDR efficiency can be enhanced by cell cycle synchronization, NHEJ inhibitors like SCR7, and Cas9 variants or fusions.
Selection and screening are mandatory; use outward-facing PCR primers and Sanger sequencing to confirm correct integration.
Mosaicism and off-target effects are the main risks in embryo and in vivo knock-in; validate thoroughly before drawing conclusions.